Docoh
Loading...

124 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
to make any sales of our common stock under the Sales Agreement and no assurance can be given that we will sell any shares under the Sales Agreement
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
be no assurance that the Sales Agent will be successful in selling Placement Shares, and (ii) the Sales Agent will incur no liability or obligation … to the Sales Agent (i) the written opinions and negative assurance of Foley & Lardner LLP, counsel to the Company, or other counsel reasonably satisfactory
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
be no assurance that we will obtain the necessary funding in the future when necessary. We had 0 revenue during the six months ended June 30, 2021 and do … to actively pursue financing alternatives, but there can be no assurance that we will obtain the necessary funding in the future when necessary. Our
10-Q
2021 Q2
EX-31.1
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
10-Q
2021 Q2
EX-31.2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
, compound property optimization, formulation development, delivery system development, quality assurance and quality control development, statistical … directed to making, having made, producing, Manufacturing, processing, filling, finishing, packaging, labeling, quality assurance testing and release
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
to actively pursue financing alternatives, but there can be no assurance that we will obtain the necessary funding in the future when necessary. We had … , no assurance is provided that we will be able to obtain full or partial forgiveness of the PPP Loan. As of March 31, 2021, $144,888 of the total $162,459
10-Q
2021 Q1
EX-31.1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
10-Q
2021 Q1
EX-31.2
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
10-K
2020 FY
EX-31.2
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
10-K
2020 FY
EX-31.1
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
, which include requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation … of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. In addition, in most foreign
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
used the proceeds of our PPP Loan for payroll costs. However, no assurance is provided that we will be able to obtain forgiveness of the PPP Loan … were not effective in providing reasonable assurance in the reliability of our report as of the end of the period covered by this report. In our 2019
10-Q
2020 Q3
EX-31.1
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
10-Q
2020 Q3
EX-31.2
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
, as Representatives of the several Underwriters, the opinion and negative assurance statement of Foley & Lardner LLP, counsel for the Company, dated … of the several Underwriters, such opinion or opinions and negative assurance statement of Faegre Drinker Biddle & Reath LLP, counsel for the Underwriters, dated
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
on the completion of this offering. Our common stock will commence trading on Nasdaq on October 2, 2020. There can be no assurance that a trading market … provide no assurance as to the reliability of any other information that others may give you. This prospectus is an offer to sell only the shares
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
on the completion of this offering. We have assumed a public offering price of $5.00 per share. There is no assurance that this offering will be completed … offering price or market price of our common stock on Nasdaq and there can be no assurance that a trading market will develop for our shares of common
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
. There is no assurance that this offering will be completed, or as to the terms of this offering. In addition, the closing sales price of our common stock … as reported on the OTCQB may not be indicative of the final offering price or market price of our common stock on Nasdaq and there can be no assurance